drugset / Trial / NCT06065189
Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major
Phase 0
Completed
2 enrolled
Children's Hospital of Fudan University
CorrectSequence Therapeutics Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of base-edited autologous hematopoietic stem cell transplantation(CS-101) in treating patients with β-thalassemia major.
Timeline
- Start
- 2023-11-07
- Primary completion
- 2025-08-12
- Completion
- 2025-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS-101 | Cell therapy | — | — |